12-September-2023
A new Russian drug for the relief of headaches caused by migraine attacks, Relonova® (INN Rizatriptan), developed and produced by the Russian pharmaceutical company NovaMedica, has become available for purchase on online pharmacy websites, which will make it easier for patients to access it.
Production of one of the world's most sought-after drugs for migraine therapy starts in Moscow
12-July-2023
The Russian pharmaceutical company NovaMedica has announced the production and market launch of the first large batch of the drug Relonova® intended for relief of migraine-associated headaches. The drug is based on the Rizatriptan molecule, which for the first time is fully localized in Russia, from development and manufacturing to introduction in the specialist prescription practice. Rizatriptan is one of the most sought-after molecules in the world for relief and alleviation of migraine symptoms.
Production of one of the world’s most sought-after drugs for migraine therapy starts in Moscow
13-July-2023
Production of one of the world’s most sought-after drugs for migraine therapy starts in Moscow
12-July-2023
12-April-2023
NovaMedica will produce migraine drug Relonova in Moscow
23-March-2023
NovaMedica team wishes you a Merry Christmas and a Happy New Year!
26-December-2023
Grand finale from a veritable stalwart of neuroscience
09-November-2023
Battle of pharma advocates – in search of the ideal migraine therapy
09-November-2023
Innovative method could offer cost-effective sterilisation approach
19-March-2024
In 2023, Russia has registered 540 drugs
19-March-2024
Rapid pseudomonas aeruginosa detection method developed
18-March-2024